Bioanalysis
Bioanalysis
What Does it Take? | Biologic and Biosimilar Clinical Trials
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
It’s the much-anticipated Part II of our “What Does it Take” series (insert glorious trumpet announcement sound here).
Quantitation of Insulin Glargine and Major Metabolites in Human Plasma Using Hybrid LBA-LC/MS with Automated Magnetic Particle Processing
Impact of Plasma Hemolysis on the Recovery of Phenprocoumon in LC-MS/MS Chiral Assay
A Strategy for Maintaining Chromatographic Peak Shape Due to Incompatible Extract and Mobile Phase by LC-MS/MS
Protein Quantitation Workflows using the TripleTOF 6600: A Case Study for Rituximab
Comparison of Bottom-Up and Top-Down Analytical Methodologies for the Quantitative Bioanalysis of Large Therapeutic Peptides in Biological Matrix
Method Development of an Automated Hybrid LBA-LC/MS Assay for the Quantitative Bioanalysis of the Biotherapeutic Teriparatide in Human Plasma
Application of Complementary HRMS Methodologies for a Thorough Biosimilar Comparability Assessment
7th GCC Insights: Incurred Samples Use; Fit-for-Purpose Validation, Solution Stability, Electronic Laboratory Notebook and Hyperlipidemic Matrix Testing
2013 White Paper on recent issues in Bioanalysis: 'Hybrid' - The Best of LBA and LCMS